Celgene beats US antitrust claims by Blue Cross Blue Shield over Pomalyst
Celgene, Anthony Insogna and Jerome Zeldis have been granted dismissal of Blue Cross Blue Shield’s US antitrust claims that Celgene obtained patents on the drug Pomalyst fraudulently to monopolize the relevant...To view the full article, register now.
Already a subscriber? Click here to view full article